Klinik für Innere Medizin 3, Schwerpunkt Pneumologie

Universitätsklinik der Paracelsus Medizinischen Privatuniversität

Bild-Brückl Prof. Dr. med. Wolfgang Brückl, Oberarzt

Leitung Pneumologische Onkologie

Tel: 0911/398-2674
E-Mail: wolfgang.brueckl@klinikum-nuernberg.de
Fax: 0911/398-2441

Prof.-Ernst-Nathan-Str. 1
90419 Nürnberg
Deutschland
Haus: 14, 4

Qualifikationen

                       

Schwerpunkte:

[nach oben]

 

Publikationen

•Naschberger E, Croner RS, Merkel S, Dimmler A, Tripal P, Amann KU, Kremmer E, Brueckl WM, Papadopoulos T, Hohenadl C, Hohenberger W, Stürzl M.

Angiostatic immune reaction in colorectal carcinoma: Impact on survival and

Perspectives for antiagiogenic therapy.

Int J Cancer 123 (2008) 2120-2129

 

•Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Roedel F, Dimmler A, Dorlaque L, Hohenberger W, Hahn EG, Brueckl W.

Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal cancers and their synchronous liver metastases

Anticancer Res (2008) in press

 

•Croner RS, Förtsch T, Brueckl WM, Roedel F, Roedel C, Papadopoulos T, Brabletz T, Kirchner T, Sachs M, Behrens J, Klein-Hitpass L, Stürzl M, Hohenberger W, Lausen B. Molecular signature for lymphatic meteastasis in colorectal carcinomas.

Ann Surg 247 (2008) 803-810

 

•Brueckl WM, Schoeberl A, Wirtz RM, Murray S, Hahn EG, Wiest GH.

Increased vascular-endothelial growth factor (VEGF) tumour expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC)

J Thorac Oncol 3 (2008): 314-316

 

•Brueckl WM, Herbst L, Lechler A, Fuchs F, Schoeberl A, Zirlik S, Klein P, Brunner TB, Papadopoulos T, Hohenberger W, Hahn EG, Wiest GH.

Predictive and prognostic factors in small  cell lung carcinoma (SCLC) – analysis from routine clinical practice.

Anticancer Res 26 (2006): 4825-4832

 

•Brueckl WM, Fritsche B, Seifert B, Boxberger F, Albrecht H, Croner RS, Wein A, Hahn EG.

Non-compliance in surveillance for patients with previous resection of large (>1cm) colorectal adenomas.

World J Gastroenterol 12 (2006):7313-7318

 

•Brunner TB, Tinkl D, Grabenbauer GG, Meyer T, Brueckl WM, Sauer R.

Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.

Strahlenther Oncol 182 (2006):210-215

 

•Brueckl WM, Grombach J, Wein A, Ruckert S, Porzner M, Dietmaier W, Rummele P, Croner RS, Boxberger F, Kirchner T, Hohenberger W, Hahn EG, Jung A.

Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI).

Cancer Letters 223 (2005): 137-142

 

•Brueckl WM, Ballhausen WG, Fortsch T, Gunther K, Fiedler W, Gentner B, Croner R, Boxberger F, Kirchner T, Hahn EG.

Genetic testing for germline mutations of the APC gene in patients with apparently sporadic desmoid tumors but a family history of colorectal carcinoma.

Dis Colon Rectum 48 (2005): 1275-1281

 

•Croner RS, Peters A, Brueckl WM, Matzel KE, Klein-Hitpass L, Brabletz T, Papadopoulos T, Hohenberger W, Reingruber B, Lausen B.

Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma.

Cancer 104 (2005): 395-404

 

•Croner RS, Brueckl WM, Reingruber B, Hohenberger W, Guenther K.

Age and manifestation related symptoms in familial adenomatous polyposis.

BMC Cancer 2 (2005) 24-27

 

•Croner RS, Foertsch T, Brueckl WM, Guenther K, Siebenhaar R, Stremmel C, Matzel KE, Papadopoulos T, Kirchner T, Behrens J, Klein-Hitpass L, Stuerzl , Hohenberger W, Reingruber B.

Common denominator genes that distinguish colorectal carcinoma from normal mucosa.

Int J Colorectal Dis 20 (2005): 353-362

 

•Werhan F, Rodel F, Grabenbauer GG, Amann K, Brueckl WM, Schultze-Mosgau S.

Transforming growth factor beta 1 dependent regulation of Tenascin-C in radiation impaired wound healing.

Radiother Oncol 72 (2004): 297-303

 

•Croner RS, Guenther K, Foertsch T, Sciebenhaar R, Brueckl WM, Stremmel C, Hlubek F, Hohenberger W, Reingruber B.

Tissue preparation for gene expression profiling of colorectal carcinoma: three alternatives to laser microdissection with preamplification.

J Lab Clin Med 143 (2004): 344-351

 

•Link K, Happich K, Schirner I, Jüngert B, Brückl V, Männlein G, Brückl WM, Merkel S, Göhl J, Hohenberger W, Hahn EG, Wein A.

Palliative second-line treatment with weekly high-dose 5-Fluorouracil as 24-hour infusin and folinic acid (AIO) plus Oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).

Anticancer Res 24 (2004): 385-392

 

•Stickel F, Brückl V, Schirner I, Brueckl WM, Männlein G, Mühlbauer S, Göhl J, Hohenberger W, Schuppan D, Hahn EG, Wein A.

Weekly high-dose 5-FU as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer (CRC) pretreated with AIO plus Oxaliplatin (L-OHP).

Anticancer Drugs 14 (2003): 745-749

 

•Brueckl WM, Heinze E., Milsmann C, Wein A, Koebnick C, Jung A, Boxberger F, Brabletz T, Günther T, Kirchner T, Hahn EG, Hohenberger W, Becker H, Reingruber B.

Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small bowel.

Cancer Letters 203 (2003): 181-190

 

•Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Guenther K, Jung A, Boxberger F, Kirchner T, Hohenberger W, Hahn EG, Wein A.

Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line treatment with weekly 24-hour infusion of high-dose 5-FU and folinic acid.

Anticancer Res 23 (2003): 1773-1778

 

•Wein A, Riedel C, Brückl W, Merkel S, Ott R, Hanke B, Baum U, Fuchs F, Günther K, Reck T, Papadopoulos T, Hahn EG, Hohenberger W.

Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-h infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.

Oncology 64 (2003): 131-38.

 

•Wiest GH, Harsch IA, Fuchs FS, Kitzbichler S, Bogner K, Brueckl WM, Hahn EG, Ficker JH.

Initiation of CPAP therapy for OSA: Does prophylactic humidification during CPAP pressure titration improve initial patient acceptance and comfort?

Repiration 69 (2002): 406-12

 

•Ruckert S2, Hiendlmeyer E2, Brueckl WM2, Oswald U, Beyser K, Dietmayer W, Haynl A, Koch C, Rüschoff J, Brabletz T, Kirchner T, Jung A.

T-cell factor-4 frameshift mutations occur frequently in human microsatellite instability-high colorectal carcinoma but do not contribute to carcinogenesis.

Cancer Res 62 (2002): 3009-13 (2) Equally contributed to the mansucript

 

•Nusko G, Mansmann U, Wiest G, Brueckl WM, Kirchner T, Hahn EG.

Right sided shift found in metachronous colorectal adenomas.

Endoscopy 33 (2001): 574-79.

 

•Brueckl WM, Preuss JM, Wein A, Jung A, Brabletz T, Pflüger R, Wiest GH,Wölfl C, Kirchner T, Hahn EG, Hohenberger W, Günther K.

Ki-67 expression and residual tumour (R) classification are associated with disease-free survival in desmoid tumour patients.

Anticancer Res 21 (2001): 3615-20.

 

•Wein A, Riedel C, Köckerling F, Martus P, Baum U, Brueckl WM, Reck T, Ott R, Hänsler J, Bernatik T, Becker D, Schneider T, Hohenberger W, Hahn EG.

Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid.

Ann Oncol 12 (2001): 1721-27.

 

•Bittorf B, Kessler H, Merkel S, Brückl WM, Wein A, Ballhausen WG, Hohenberger W, Günther K.

Multiple primary malignancies: An epidemiological and pedigree analysis of 57 patients with at least three tumours.

Eur J Surg Oncol 27 (2001): 302-13

 

•Wiest GH, Fuchs FS, Harsch IA, Pour Schahin S, Lampert S, Brueckl WM, Hahn EG, Ficker JH.

Reproducibility of a Standardized Titration Procedure for the Initiation of Continuous Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnoea.

Respiration 68 (2001): 145-50

 

•Brueckl WM, Limmert T, Brabletz T, Guenther K, Jung A, Hermann K, Wiest GH, Kirchner T, Hohenberger W, Hahn EG, Wein A.

Mismatch Repair Deficiency in Sporadic Synchronous Colorectal Cancer.

Anticancer Res 20 (2000): 4727-32.

 

•Wiest GH, Fuchs F, Brueckl WM, Nusko G, Harsch IA, Hahn EG, Ficker JH.

In vivo efficacy of heated and non-heated humidifiers during nCPAP-therapy for obstructive sleep apnoea.

Resp Med 94 (2000): 364-68.

 

•Wiest GH, Lehnert G, Brueckl WM, Meyer M, Hahn EG, Ficker JH.

A heated humidifier reduces upper airway dryness during continuous positive airway pressure therapy.

Resp Med 93 (1999): 21-26.

 

•Meindl A, Hosenfeld D, Brückl W, Schuffenhauer S, Jenderny J, Bacskulin A, Opperman HC, Swensson O, Bouloux P, Meitinger T.

Analysis of a terminal Xp22.3 deletion in a patient with six monogenic disorders: implications for the mapping of X-linked ocular albinism.

J Med Genet 30 (1993): 838-43.

 

 

Übersichtsarbeiten und Kasuistiken

 

•Brückl WM, Lampert S, Zirlik S, Hahn EG, Wiest GH.

Medikamentöse Therapie des kleinzelligen Bronchialkarzinoms (SCLC) –Neue

Molekulare Therapieansätze.

Pneumologie 62 (2008): 23-30

 

•Wiest GH, Brückl WM.

Pronounced face swelling. What cause do you suspect. Casuistic report.

MMW Fortschr. Med 149 (2007) 5                                                                                  

 

•Zirlik S, Lampert S, Hahn EG, Wiest GH, Brückl WM.

Auf dem Weg zu einer individualisierten Therapie des nicht-kleinzelligen

Bronchialkarzinoms (NSCLC) – Stellenwert molekularer Prädiktions- und

Prognosefaktoren-

Pneumologie 61 (2007) 731-738

 

•Gentner B, Kraus C, Schwab D, Benninger J, Wein A, Hahn EG, Brueckl WM.

A case of attenuated familial adenomatous polyposis coli (AFAP).

Z Gastroenterol 43 (2005): 591-595

 

 

•Rödel F, Brückl W.

DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study.

Strahlenther Onkol 179 (2003): 274-75

 

•Boxberger F, Harsch IA, Brueckl WM, Hautmann M, Baum U, Hahn EG, Wein A.

Chronische Gicht: Fallbeispiel einer ausgeprägten Verlaufsform.

Medizinische Klinik 98 (2003): 646-647

 

•Boxberger F, Jüngert B, Brueckl V, Brueckl WM, Hautmann M, Hohenberger W,
Hahn EG, Wein A.

Palliative Chemotherapy with Gemcitabine and Weekly High-Dose 5-Fluorouracil as 24-h Infusion in Metastatic Biliary Tract and Gallbladder Adenocarcinomas.

Anti-Cancer Drugs 14 (2003): 87-90

 

•Boxberger F, Happich K, Schirner I, Brückl WM, Hohenberger W, Hahn EG, Wein A.

Palliative Second-Line Treatment with Oxaliplatin, Gemcitabine and Weekly High-Dose

5-Fluorouracil as 24-h Infusion in Patients with Metastatic Pancreatic Adenocarcinoma.

Z Gastroenterol 40 (2002): 881-883

 

•Wein A, Riedel C, Brückl W, Kastl S, Reingruber B, Hohenberger W, Hahn EG.

Weekly 24-h infusion of high-dose 5-Fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer.

Z Gastroenterol 39 (2001): 153-56.

 

•Wein A, Riedel C, Hanke B, Lampert S, Brückl W, Reingruber B, Hohenberger W, Hahn EG.
Verbesserungen der palliativen Behandlung des kolorektalen Karzinoms.

Dtsch med Wschr 125 (2000): 121-25.

 

•Brückl WM, Jung A, Wein A, Brabletz T, Guenther K, Nusko G, Hahn EG.

Microsatellite instability in colorectal adenomas: relevance and clinical importance.
Int J Colorect Dis 15 (2000): 189-96.

 

•Brückl WM, Wein A, Riedel C, Wiest GH, Hohenberger W, Hahn EG.

Retroperitonealer Desmoidtumor mit Niereninsuffizienz bei familiärer adenomatöser Polyposis.

Dtsch med Wschr 125 (2000): 81-84.

 

•Wein A, Riedel C, Köckerling F, Haack A, Brückl W, Hohenberger W, Hahn EG.

Successful Neoadjuvant Chemotherapy of Nonresectable Colorectal Liver Metastases: An Interdisciplinary Approach.

Onkologie 22 (1999): 54-56.

 

•Brückl WM, Ficker JH, Wiest GH, Hahn EG.

Mikrosatelliteninstabilität in Bronchialkarzinomen: ein molekulargenetischer Aspekt der Tumorentstehung und – therapie.

Atemw – Lungenkrkh 24 (1998): 198-204.

 

[nach oben]

 

Patentschriften

Tumormarker zur Diagnose von Karzinomen und / oder davon abstammender Metastasen

PD Dr. W. Brückl, PD Dr. A. Wein, Dr. M. Munnes

Deutsches Patentamt DE 10/2004 037 860.6

Europäisches Patentamt WO 2006 015742

www.wipo.int/pctdb/en/wo.jsp?wo=2006015742

 

• Prediction and prognosis of metastatic CRC by determining serum parameters

Dr. R. Wirtz, M. Averdick, Dr. R. Thiel, PD Dr. A. Wein, PD Dr. W. Brückl

United States Patent and Trademark Office WO 2007 016367

www.wipo.int/pctdb/en/wo.jsp?wo=2007016367

 

Prediction and prognosis of metastatic CRC by expression profiling in fresh and fixed tumor tissue

Dr. R. Wirtz, Dr. M. Munnes, Dr. A. Schuppert, PD Dr. A. Wein, PD Dr. W. Brückl

United States Patent and Trademark Office (eingereicht 2007)

 

Molecular markers to predict response to chemotherapy and EGFR family inhibition by targeted strategies in lung cancer

PD Dr. W. Brückl, Dr. R. Wirtz

United States Patent and Trademark Office 2007 (eingereicht 12/2007)

 

[nach oben]

 

[nach oben]

Publikationen

 

[nach oben]

 
Es öffnet sich eine Seite auf klinikum-nuernberg.de mit Notfallinformationen
Bitte spenden sie
Abstandhalter
AbstandhalterMarke Stadt Nürnberg

Übersicht

Aktuelles

Unternehmen

Bildung

Partner

Service

Zentren